interaction records 54 assistance programs 55 0 personal data stored

Copay help by condition · Immune system, transplant and skin · read 2026-11-08

Rheumatoid arthritis (RA): which charitable copay funds are open

The one fund we hold for Rheumatoid arthritis is closed or at capacity right now (read 2026-11-08).

Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.

If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.

Funds by status: 1 closed or at capacity1 closed

Swipe to read across

Funds we hold for Rheumatoid arthritis, by the status each page gave on the day we read it.
What this is not. A record of what fund pages and FDA labels say, not advice and not a check of whether you qualify. US funds only. This page covers charitable funds from the organizations we read, the costs around a condition those funds pay for, and the drugs whose FDA label names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

Every fund we hold for Rheumatoid arthritis

  • Closed or at capacityRheumatoid arthritis (RA)

    TotalAssist (Patient Advocate Foundation copay funds) ·

    Award level: $4,000Insurance supported: Medicaid, Medicare, TRICARE

    The page lists the fund as Closed. Source page

Drugs whose FDA label names Rheumatoid arthritis

12 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 9 have a program (in our assistance finder or on the program's own page) and 1 has a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.

DrugWhat the FDA label saysManufacturer programMedicare negotiated price
Orencia
Abatacept
Every route for this drug
... the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Label on openFDA, read 2026-11-10
RA Medication Assistance (Multiple Programs)
Bristol Myers Squibb Patient Assistance Foundation (program page)
selected by CMS for 2028; price not yet published
Enbrel
Etanercept
Every route for this drug
Rheumatoid Arthritis (RA) ( 1.
Label on openFDA, read 2026-11-10
Enbrel Support (via Amgen)
RA Medication Assistance (Multiple Programs)
Amgen Safety Net Foundation (program page)
$2,418.70 for a 30-day supply, effective 2027-01-01
Xeljanz
Tofacitinib
Every route for this drug
Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers.
Label on openFDA, read 2026-11-10
Pfizer RxPathways Limited
no new patients starting July 1, 2026
RA Medication Assistance (Multiple Programs)
selected by CMS for 2028; price not yet published
Humira
Adalimumab
Every route for this drug
Rheumatoid Arthritis (RA) ( 1.
Label on openFDA, read 2026-11-10
Humira Complete (via myAbbVie Assist)
myAbbVie Assist
RA Medication Assistance (Multiple Programs)
not in the CMS negotiated-price file
Restasis
Cyclosporine
Every route for this drug
Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to ...
Label on openFDA, read 2026-11-10
myAbbVie Assistnot in the CMS negotiated-price file
Simponi
Golimumab
Every route for this drug
Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.
Label on openFDA, read 2026-11-10
Johnson & Johnson Patient Assistance Programnot in the CMS negotiated-price file
Kevzara
Sarilumab
Every route for this drug
... adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Label on openFDA, read 2026-11-10
RA Medication Assistance (Multiple Programs)not in the CMS negotiated-price file
Actemra
Tocilizumab
Every route for this drug
Rheumatoid Arthritis (RA) ( 1.
Label on openFDA, read 2026-11-10
Genentech Patient Foundation
stops accepting new enrollments effective January 1, 2027; all Foundation support ends December 31, 2027
RA Medication Assistance (Multiple Programs)
not in the CMS negotiated-price file
Rinvoq
Upadacitinib
Every route for this drug
RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
Label on openFDA, read 2026-11-10
Rinvoq Complete (via AbbVie)
myAbbVie Assist
RA Medication Assistance (Multiple Programs)
not in the CMS negotiated-price file
Cimzia
Certolizumab Pegol
Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.
Label on openFDA, read 2026-11-10
not in our assistance finderselected by CMS for 2028; price not yet published
Remicade
Infliximab
Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with ...
Label on openFDA, read 2026-11-10
not in our assistance findernot in the CMS negotiated-price file
1 drug whose label names more than 8 conditions

Broad labels, such as corticosteroids, list many conditions in one sentence. They are shown apart so they do not crowd the drugs written for Rheumatoid arthritis.

DrugWhat the FDA label saysManufacturer programMedicare negotiated price
Acthar
Corticotropin
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy);
Label on openFDA, read 2026-11-10
not in our assistance findernot in the CMS negotiated-price file

No broader or more specific condition page for this one.

Group: Immune system, transplant and skin. All conditions: the condition index. Fund board for every condition: charitable copay fund status.

What changed

First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.

This page as data

The same facts as JSON, each fund with its source URL and read date: rheumatoid-arthritis.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is there an open charitable copay fund for Rheumatoid arthritis?

As read on 2026-11-08, none of the 1 funds we hold for Rheumatoid arthritis say they are open. Funds reopen, so use the alert on this page.

Which organizations run funds for Rheumatoid arthritis?

TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.

Does an open fund mean I qualify?

No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.

How current is this page?

Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.